Oil Prices Rise as US-Iran Talks Stall, Inflation Risks Grow 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
US Dollar Near Two-Month Low as Markets Await Inflation Data 
UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing 
South Korean Won Leads Asian FX Losses as Dollar Rises 
Japan Executives Warn Weak Yen and Currency Volatility Threaten Economy 
European Stocks Flat as Oil Prices Rise, US CPI in Focus 
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge 
Gold Prices Rise as Fed Rate Hike Bets Ease 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
Singapore Raises 2026 GDP Growth Forecast to 4.5%-5.5% as AI Boom Fuels Economy 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Asian Stocks Rise as Weak US Jobs Data Eases Fed Rate Hike Bets 
Singapore Raises 2026 GDP Growth Forecast as AI Demand Fuels Economy 
China’s WuXi AppTec has signed an agreement to sell its gene therapy manufacturing arm, WuXi Advanced Therapies, to U.S.-based Altaris LLC, following mounting restrictions on Chinese firms in the United States over national security concerns. The deal also includes Oxford Genetics in the UK.
WuXi AppTec Sells Gene Therapy Unit Amid US Restrictions
The Chinese company WuXi AppTec announced on Tuesday that its subsidiaries have inked a contract with the private equity firm Altaris LLC, which is based in the United States, for the sale of its cell and gene therapy manufacturing unit, WuXi Advanced Therapies, for an amount that has not been disclosed.
Due to worries regarding national security, the corporation, along with other Chinese businesses, has been at the focus of new regulations that have been enacted in the United States with the intention of restricting their businesses in the United States, Investing.com shares.
US Legislation Targets Chinese Companies Over National Security Concerns
In September, the House of Representatives of the United States of America enacted a bill that would bar the federal government from entering into contracts with specified companies and those that do business with those companies.
The laws are intended to protect the personal health and genetic information of Americans from foreign adversaries.
Shift in US Pharma and Biotech Supply Chains
Additionally, they intend to encourage pharmaceutical and biotechnology businesses in the United States to reduce their reliance on China for a variety of activities, including the manufacturing of medicinal ingredients and early research.
The United Kingdom-based operating company of the WuXi ATU business, Oxford Genetics, will be sold to Altaris LLC, according to a statement made by WuXi.
Altaris declined to comment further than the information that was provided, while WuXi AppTec did not react to a request for comment made by Reuters by the company.
